MindBio Therapeutics Corp. reported that the final milestone in the Company’s Phase 2A Microdosing Depression Clinical Trial, the 6-month post treatment milestone measuring the “severity of depression” has been completed. The completion of this important milestone comes as the Company progresses more than a third of the way through its Phase 2B Randomized Controlled Trial in 90 patients with Major Depressive Disorder.
The Company has already discovered much about its lead candidate drug, MB22001 from Phase 1 and Phase 2A clinical trials. Depressed patients experienced a 60% drop in depressive symptoms and 53% of patients entering the trial with Depression, at week 8 were in remission from their depression with a mean 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale). Prior trial results using MB22001 recorded statistically significant improvements in total sleep time and quality of sleep and statistically significant increases in subjective feelings of “H happiness”, “Social Connectivity”, “Energy”, “Creativity” and “Wellness” with reduced “Anger” and “Irritability”.
The company have now discovered the antidepressant response is sustained at 1 month and 3 months post an 8 week treatment cycle. The Company will report on the important 6-month post treatment milestone in the coming fortnight. MB22001 is a promising and potential market disruptive medicine for treating depressive illness.
The Company is now running two significant Phase 2B clinical trials with dosing underway and a third Phase 2B trial that has now also been approved in women’s health. In a series of world firsts, each of these trials is approved for the take-home use of MB22001, a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing. There are only a handful of public companies in the world that have progressed to Phase 2 and Phase 3 clinical trials in psychedelic medicines.
MindBio is the most advanced clinical trial stage biopharma company listed on the Canadian Securities Exchange and the only company at this level that is not listed on a senior exchange. The Company will provide further updates in due course.